Tamoxifen therapy of metastatic breast cancer

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Inhibition of estrogen action at the target tissue level with the antiestrogen, tamoxifen, has proved highly successful in the treatment of hormone-responsive breast cancer. In randomized clinical trials involving postmenopausal patients, tamoxifen has been found to be as effective as high-dose estrogens, androgens, progestins, and the aromatase inhibitor, aminoglutethimide. Because of its remarkable lack of significant toxicity, tamoxifen is now considered the first endocrine treatment of choice of hormone-responsive postmenopausal breast cancer. Although effective in a significant fraction of premenopausal patients, tamoxifen cannot be considered a substitute for ovariectomy because it usually does not suppress menses and because response to castration may occur after progression during antiestrogen therapy. Current evidence suggests that there is no major advantage in combining tamoxifen with other endocrine therapies or chemotherapy. At present, it appears preferable to use different modalities of endocrine therapy sequentially in those patients with hormone-responsive cancers. Chemotherapy should be delayed until maximum benefit has been obtained from endocrine therapy.

Original languageEnglish (US)
Pages (from-to)290-299
Number of pages10
JournalJournal of Laboratory and Clinical Medicine
Volume109
Issue number3
StatePublished - 1987

Fingerprint

Tamoxifen
Breast Neoplasms
Estrogen Receptor Modulators
Chemotherapy
Hormones
Estrogens
Aminoglutethimide
Therapeutics
Aromatase Inhibitors
Drug Therapy
Progestins
Menstruation
Castration
Androgens
Ovariectomy
Toxicity
Tissue
Randomized Controlled Trials
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

@article{51aba262569e4eaeab127ce9c5ab6983,
title = "Tamoxifen therapy of metastatic breast cancer",
abstract = "Inhibition of estrogen action at the target tissue level with the antiestrogen, tamoxifen, has proved highly successful in the treatment of hormone-responsive breast cancer. In randomized clinical trials involving postmenopausal patients, tamoxifen has been found to be as effective as high-dose estrogens, androgens, progestins, and the aromatase inhibitor, aminoglutethimide. Because of its remarkable lack of significant toxicity, tamoxifen is now considered the first endocrine treatment of choice of hormone-responsive postmenopausal breast cancer. Although effective in a significant fraction of premenopausal patients, tamoxifen cannot be considered a substitute for ovariectomy because it usually does not suppress menses and because response to castration may occur after progression during antiestrogen therapy. Current evidence suggests that there is no major advantage in combining tamoxifen with other endocrine therapies or chemotherapy. At present, it appears preferable to use different modalities of endocrine therapy sequentially in those patients with hormone-responsive cancers. Chemotherapy should be delayed until maximum benefit has been obtained from endocrine therapy.",
author = "Andrea Manni",
year = "1987",
language = "English (US)",
volume = "109",
pages = "290--299",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "3",

}

Tamoxifen therapy of metastatic breast cancer. / Manni, Andrea.

In: Journal of Laboratory and Clinical Medicine, Vol. 109, No. 3, 1987, p. 290-299.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tamoxifen therapy of metastatic breast cancer

AU - Manni, Andrea

PY - 1987

Y1 - 1987

N2 - Inhibition of estrogen action at the target tissue level with the antiestrogen, tamoxifen, has proved highly successful in the treatment of hormone-responsive breast cancer. In randomized clinical trials involving postmenopausal patients, tamoxifen has been found to be as effective as high-dose estrogens, androgens, progestins, and the aromatase inhibitor, aminoglutethimide. Because of its remarkable lack of significant toxicity, tamoxifen is now considered the first endocrine treatment of choice of hormone-responsive postmenopausal breast cancer. Although effective in a significant fraction of premenopausal patients, tamoxifen cannot be considered a substitute for ovariectomy because it usually does not suppress menses and because response to castration may occur after progression during antiestrogen therapy. Current evidence suggests that there is no major advantage in combining tamoxifen with other endocrine therapies or chemotherapy. At present, it appears preferable to use different modalities of endocrine therapy sequentially in those patients with hormone-responsive cancers. Chemotherapy should be delayed until maximum benefit has been obtained from endocrine therapy.

AB - Inhibition of estrogen action at the target tissue level with the antiestrogen, tamoxifen, has proved highly successful in the treatment of hormone-responsive breast cancer. In randomized clinical trials involving postmenopausal patients, tamoxifen has been found to be as effective as high-dose estrogens, androgens, progestins, and the aromatase inhibitor, aminoglutethimide. Because of its remarkable lack of significant toxicity, tamoxifen is now considered the first endocrine treatment of choice of hormone-responsive postmenopausal breast cancer. Although effective in a significant fraction of premenopausal patients, tamoxifen cannot be considered a substitute for ovariectomy because it usually does not suppress menses and because response to castration may occur after progression during antiestrogen therapy. Current evidence suggests that there is no major advantage in combining tamoxifen with other endocrine therapies or chemotherapy. At present, it appears preferable to use different modalities of endocrine therapy sequentially in those patients with hormone-responsive cancers. Chemotherapy should be delayed until maximum benefit has been obtained from endocrine therapy.

UR - http://www.scopus.com/inward/record.url?scp=0023147865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023147865&partnerID=8YFLogxK

M3 - Article

C2 - 2950193

AN - SCOPUS:0023147865

VL - 109

SP - 290

EP - 299

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 3

ER -